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Introduction: Uterine adenosarcoma (UAS), ﬁrst described by Clement and
Scully, is characterised by a benign, sometimes atypical, epithelial component
and by a sarcomatous stromal component [1]. Although this rare tumour has
generally been regarded as being of low grade malignancy, a subgroup with
sarcomatous overgrowth follows a more aggressive clinical course [2,3].
Given the paucity of data regarding hormone dependency, it was the purpose of
this study to screen for the presence of oestrogen and progesterone receptors (ER
and PR).
Patients and methods: One-hundred-and-ﬁve centres were asked to screen their
ﬁles for UAS. All sent biopsies were submitted for central pathological review.
Both macroscopic and microscopic criteria were used to establish a diagnosis.
Sarcomatous overgrowth was deﬁned when the sarcomatous component
occupied more than 25% of the total tumour volume. An immunohistochemical
ER and PR determination was performed.
Results: Twenty-eight primary UAS were stained. Sarcomatous overgrowth
could be observed in 8, whereas 1 cervical adenosarcoma was included.
Furthermore, 2 cases of recurrent UAS, one only consisting of endometrial
stromal sarcoma, were stained. UAS lacking sarcomatous overgrowth showed
ER positivity in 17/20 (85%) and 16/20 (80%) in the epithelial and sarcomatous
components, respectively. PR positivity was observed in 13/20 (65%) and 12/20
(60%) in the epithelial and sarcomatous components, respectively. In 18/20
(90%) of the cases either the ER or PR stained positive in the sarcomatous
component. UAS with sarcomatous overgrowth showed ER positivity in 4/8
(50%) and 0/8 (0%) in the epithelial and sarcomatous component, respectively.
PR positivity was observed in 2/8 (25%) and 1/8 (13%) in the epithelial and
sarcomatous component, respectively. The stromal component of both recurrent
cases stained moderately positive for ER, whereas PR was considered negative.
Discussion: The observation that the sarcomatous component of UAS without
sarcomatous overgrowth frequently expresses hormone receptors might be of
substrated clinical importance.
Firstly, this ﬁnding puts the currently used aggressive treatment modalities
including chemotherapy and radiotherapy in perspective and we hypothesise
hormonal agents may play a major role in the treatment of an apparent
hormone-sensitive disease. In order to decrease recurrence rates and increase
disease-free survival in completely or incompletely resected advanced stage UAS,
we suggest to administer serially agents that are known to act either by the ER or
PR, including progestins, aromatase inhibitors, gonadotrophin-releasing hor-
mone (GNRH) analogues and fulvestrant. These agents might also be beneﬁcial
in the recurrent setting. However, the observation that UAS with sarcomatous
overgrowth rarely express hormone receptors suggests hormonal treatment to be
of little value in this subset of patients.
Secondly, the current results question the safety of ovarian conservation and
suggest both ovaries should be removed during surgery. Thirdly, the tendency of
UAS to recur in combination with hormone receptor-positivity, suggests to
withhold hormone replacement therapy in women dealing with UAS.
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